{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Schmitt MM"],"funding":["Intramural NIH HHS"],"pagination":["e131"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9004485"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2(4)"],"pubmed_abstract":["<h4>Introduction</h4>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a prototypic monogenic autoimmune disorder caused by AIRE deficiency-mediated impaired central immune tolerance. Although multiple endocrine and non-endocrine tissues are affected in APECED, the colon is an uncommon target of autoimmune attack. Mycophenolate is a potent immunomodulatory medication that is used to treat autoimmune manifestations in patients with APECED and other autoimmune diseases.<h4>Methods</h4>We reviewed the clinical, laboratory, genetic, histological, and treatment data of mycophenolate-induced colitis in our cohort of 104 APECED patients.<h4>Discussion</h4>Among 10 mycophenolate-treated APECED patients, four (40%) developed reversible biopsy-proven mycophenolate-induced co"],"journal":["JPGN reports"],"pubmed_title":["Mycophenolate-Induced Colitis in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Patients."],"pmcid":["PMC9004485"],"funding_grant_id":["ZIA AI001175"],"pubmed_authors":["Schmitt MM","Quezado MM","Ferre EMN","Lionakis MS","Heller T","De Melo MS","Cooper MA"],"additional_accession":[]},"is_claimable":false,"name":"Mycophenolate-Induced Colitis in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Patients.","description":"<h4>Introduction</h4>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a prototypic monogenic autoimmune disorder caused by AIRE deficiency-mediated impaired central immune tolerance. Although multiple endocrine and non-endocrine tissues are affected in APECED, the colon is an uncommon target of autoimmune attack. Mycophenolate is a potent immunomodulatory medication that is used to treat autoimmune manifestations in patients with APECED and other autoimmune diseases.<h4>Methods</h4>We reviewed the clinical, laboratory, genetic, histological, and treatment data of mycophenolate-induced colitis in our cohort of 104 APECED patients.<h4>Discussion</h4>Among 10 mycophenolate-treated APECED patients, four (40%) developed reversible biopsy-proven mycophenolate-induced co","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2025-04-04T22:32:26.763Z","creation":"2025-02-19T03:23:46.893Z"},"accession":"S-EPMC9004485","cross_references":{"pubmed":["35425944"],"doi":["10.1097/pg9.0000000000000131"]}}